THERACLION unveils the launch of SONOVEIN® next generation. Theraclion's ambition to replace the surgical act with a robotic platform for non-invasive treatment by echotherapy is in motion. In 2021, Theraclion has developed its varicose veins market, due to its SONOVEIN® device's effectiveness.

SONOVEIN® has thus recently expanded into new markets such as Italy and Serbia. The robotic platform is now in the hands of vascular surgery key opinion leaders in the main European markets. Moreover, in September, the FDA approved the first echotherapy for varicose veins trial in the United States.

First treatments in China with SONOVEIN® are opening up possibilities within the Asian market. This strong capacity development on a global market of $10 billioni paves the way for extension to leading global health centers. Theraclion strongly invested in the technological development of SONOVEIN®, to enable the first phase of an Artificial Intelligence (AI) pivot.

The 2022 SONOVEIN® will allow technical and per-operative data collection to create deep learning image processing models. These models will then be gradually deployed in the new versions of the device along with additional data collection features. This breakthrough will be possible due to the unique robotic and imaging capabilities of SONOVEIN®.

This innovation will thus unleash the full potential of Theraclion's technology. The aim is to eventually deliver a universal, non-invasive, AI-assisted treatment, sparing physicians the training time and bringing an optimal quality of care to patients. Furthermore, Theraclion is giving a new boost to its thyroid and breast cancer markets with ECHOPULSE®.

In June, Theraclion indeed launched a cutting-edge research collaboration with the University of Virginia Cancer Center (USA) in breast cancer treatment with HIFU.